Howard Hughes Medical Institute’s Alexion Pharmaceuticals ALXN Stock Holding History

Howard Hughes Medical Institute’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-273	Closed	-$43K	–	191
2015 Q3	$43K	Buy	+273	New	+$49.8K	0.01%	148
2015 Q2	–	Sell	-641	Closed	-$111K	–	182
2015 Q1	$111K	Sell	641 -1,581	-71%	-$286K	0.02%	144
2014 Q4	$411K	Buy	2,222 +700	+46%	+$130K	0.11%	98
2014 Q3	$252K	Buy	1,522 +846	+125%	+$139K	0.06%	112
2014 Q2	$106K	Buy	+676	New	+$107K	0.02%	120

Other funds holding ALXN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Howard Hughes Medical Institute's ALXN Position: Q4 2015 in Review

Howard Hughes Medical Institute sold out of Alexion Pharmaceuticals (ALXN) in Q4 2015, closing a stake of 273 shares — an estimated $43K sold.

Howard Hughes Medical Institute first reported a position in ALXN in Q2 2014 and held it in 5 quarters. The position peaked at $411K in Q4 2014. 548 funds tracked by Wall St. Rank hold ALXN as of Q4 2015.

Howard Hughes Medical Institute reported no remaining Alexion Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
Howard Hughes Medical Institute sold 273 Alexion Pharmaceuticals shares in Q4 2015, an estimated $43K.
Howard Hughes Medical Institute first reported a position in Alexion Pharmaceuticals in Q2 2014 and held it in 5 quarters.
Howard Hughes Medical Institute's Alexion Pharmaceuticals position peaked at $411K in Q4 2014.
548 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2015.

Based on Howard Hughes Medical Institute's 13F filing for Q4 2015, filed 11 Feb 2016.